Bahl & Gaynor Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the fourth quarter, Holdings Channel reports. The fund owned 21,562 shares of the biopharmaceutical company’s stock after selling 779 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Gilead Sciences were worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Athena Capital Advisors LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $27,000. Advisors Preferred LLC bought a new stake in Gilead Sciences in the 4th quarter valued at $31,000. Legacy Financial Advisors Inc. boosted its stake in Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 383 shares during the period. We Are One Seven LLC bought a new stake in Gilead Sciences in the 4th quarter valued at $37,000. Finally, Larson Financial Group LLC bought a new stake in Gilead Sciences in the 4th quarter valued at $38,000. 78.23% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently issued reports on the company. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday, December 4th. Citigroup restated a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a research note on Tuesday, February 5th. Wells Fargo & Co reduced their price target on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, February 5th. Finally, Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $82.29.

NASDAQ:GILD opened at $65.63 on Friday. The firm has a market cap of $82.69 billion, a PE ratio of 10.67, a P/E/G ratio of 4.08 and a beta of 1.16. The company has a quick ratio of 3.29, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $80.90.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.78 earnings per share. On average, research analysts expect that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.84%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s dividend payout ratio is presently 37.07%.

In other news, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the sale, the director now directly owns 143,567 shares in the company, valued at approximately $9,630,474.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.16% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Position Decreased by Bahl & Gaynor Inc.” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at

Gilead Sciences Company Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: What factors cause inflation to rise?

Want to see what other hedge funds are holding GILD? Visit to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.